SCHEMBL6407531

SCHEMBL6407531

CC(C)c1ccccc1C(c1cccc2ccccc12)[C@](C)(C#N)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
SLC22A12 Q96S37 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
CYP2C9 P11712 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
ACP3 P15309 2/20 0.37
CMA1 P23946 2/20 0.37
CTSG P08311 1/20 0.37
ALOX5 P09917 1/20 0.37
KMT2A Q03164 1/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4661280 1.00 ESR1 (0.42) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4661470 1.00 ESR1 (0.42) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4659951 1.00 ESR1 (0.42) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4661381 0.85 ESR1 (0.41) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4660073 0.85 ESR1 (0.41) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4661442 0.85 ESR1 (0.55) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL6406635 0.85 ESR1 (0.55) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4659967 0.85 ESR1 (0.55) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL4661506 0.85 ESR1 (0.55) ESR1ESR2SLC22A12ALDH1A1KDM4E
SCHEMBL6401602 0.85 ESR1 (0.55) ESR1ESR2SLC22A12ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use WYETH 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use HCAR2, PCCA, MCCC2 ESR1 4557/4885ESR2 1987/4885SLC22A12 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.